The growth of the overall Patient Derived Xenograft Models Market can be attributed to the growing demand for personalized medicine, continuous support for cancer research from the public as well as private sectors, and growth in the number of R&D activities in the pharmaceutical industry. In the coming years, North America is expected to account for the largest share of the global market.

The global PDX models market is expected to reach to USD 167.6 Million by 2022 from USD 68.0 Million in 2016 at a CAGR of 16.7%.

PDX Models Market: Impact Analysis

1. Growth in the Number of Pharmaceutical R&D Activities
2. Cancer Research
3. Growing Demand for Personalized Medicine
4. Rising Demand for Humanized PDX Models
5. Regional Snapshot of the Global Patient Derived Xenograft Models Market

Key Questions Addressed in The Report:

1. Who are the top 10 players operating in the global Adhesion Barrier market?
2. What are the drivers, restraints, opportunities, and challenges in the Adhesion Barrier Industry?
3. What are the opportunities for stakeholders and provide details of the competitive landscape for key players?
4. What will be growth of Adhesion Barrier in North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa?
5. What are the Known and Unknown Adjacencies Impacting the Patient Derived Xenograft/PDX Models Market?

Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121598251

Type of PDX Models:

The mice models segment is estimated to command the largest share of the global market in 2017. The rat models segment, on the other hand, is projected to register the highest CAGR from 2017 to 2022. Growth in this market is mainly driven by the larger size of rats, which enhances surgical manipulation. The development of immunodeficient rats will drive the usage of rat models in PDX model generation.

Tumor Type:

Based on tumor type, the PDX models market has been segmented into gastrointestinal tumor models, gynecological tumor models, respiratory tumor models, urological tumor models, hematological tumor models, and other tumor models such as head & neck tumors, sarcoma, and melanoma. In 2017, the gastrointestinal tumor models segment is expected to account for the largest share of the global market.

Pre-Clinical Drug Development and Cancer Research Application:

The preclinical drug development and basic cancer research segment is expected to account for the largest share of the global patient derived xenograft models market. Growth in this segment is mainly driven by the increasing number of research activities in the field of oncology drug research.

Request Sample Report:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=121598251

Key Players:

The various players in the global PDX models industry include Crown Bioscience Inc. (US), WuXi AppTec (China), Champions Oncology, Inc. (US), The Jackson Laboratory (US), ONCODESIGN (France), Charles River Laboratories International, Inc. (US), EPO Berlin-Buch GmBH (Germany), Shanghai LIDE Biotech Co., Ltd (China), Xentech (France), Horizon Discovery Group PLC (UK), Urolead (France), and Explora BioLabs (US).

Crown Bioscience Inc. is one of the strongest players in the PDX models market, having facilities across the US, the UK, China, and Taiwan. The company focuses on discovering new oncology drugs and is continuously expanding its PDX models bank to recapitulate the diversity and complexity of human cancer biology in the laboratory. The company is strongly engaged in organic and inorganic growth strategies like expansions and agreements/partnerships/collaborations, respectively.